Blue Shield of California Slashes Humira Biosimilar Prices in Landmark Deal
Blue Shield of California Slashes Humira Biosimilar Prices in Landmark Deal
However, it has faced criticism for its high pricing and extended market exclusivity, which ended in January 2023.Blue Shield of California is shaking up the pharmacy landscape with a landmark deal to drastically reduce the price of a biosimilar alternative to AbbVie Inc.'s (NYSE:ABBV) Humira, one of the world's most expensive and widely used drugs.
加州藍盾正在通過一項具有里程碑意義的協議來動搖藥房格局，該協議旨在大幅降低艾伯維公司的生物仿製藥替代品的價格。”s（紐約證券交易所代碼：ABBV）Humira，世界上最昂貴、使用最廣泛的藥物之一。
Humira, approved by the FDA in 2002, has long dominated the market, treating conditions like arthritis and Crohn's disease.
Humira於2002年獲得美國食品藥品管理局的批准，長期以來一直在市場上佔據主導地位，治療關節炎和克羅恩氏病等疾病。
Also Read: AbbVie's Arthritis Drug Humira Retains Market Dominance Despite Biosimilar Competition, Challenges Biosimilar Industry Viability.
另請閱讀：儘管存在生物仿製藥競爭，但艾伯維的關節炎藥物Humira仍保持市場主導地位，這挑戰了生物仿製藥行業的可行性。
However, it has faced criticism for its high pricing and extended market exclusivity, which ended in January 2023.
但是，它因其高昂的價格和延長的市場排他性而受到批評，這種獨家經營權於2023年1月結束。
Blue Shield, which processes around 40,000 Humira prescriptions annually, spends more on the drug than any other medication for its members, making this price-cutting move both timely and essential for addressing the rising cost of healthcare.
Blue Shield每年處理約40,000張Humira處方，其成員在該藥物上的支出超過任何其他藥物，這使得這一降價舉措對於解決不斷上漲的醫療保健成本既及時又必不可少。
The nonprofit health plan announced that it would purchase Fresenius Kabi's FDA-approved biosimilar adalimumab-aacf at a net price of $525 per monthly dose, a significant reduction from Humira's market-reported price of $2,100.
該非營利性健康計劃宣佈，它將以每劑每月525美元的淨價收購費森尤斯·卡比經美國食品藥品管理局批准的生物仿製藥adalimumab-aacf，比Humira市場公佈的2,100美元的價格大幅下降。
The deal, facilitated by Evio Pharmacy Solutions, aims to eliminate excessive markups typically imposed by pharmacy benefit managers (PBMs) in the current drug supply chain.
該協議由Evio Pharmacy Solutions促進，旨在消除當前藥品供應鏈中藥房福利經理（PBM）通常徵收的過高加價。
The new pricing model is part of Blue Shield's Pharmacy Care Reimagined initiative, which rethinks traditional PBM structures to ensure more transparent and affordable pricing.
新的定價模式是藍盾重新構想的藥房護理計劃的一部分，該計劃重新考慮了傳統的PbM結構，以確保更透明和更實惠的定價。
The aligned incentives and simplified supply chain have enabled Blue Shield to provide Fresenius Kabi's biosimilar to its members. Starting in January 2025, most commercial members are expected to pay $0 out of pocket.
一致的激勵措施和簡化的供應鏈使藍盾能夠向其成員提供費森尤斯·卡比的生物仿製藥。從2025年1月開始，預計大多數商業會員將自付0美元。
This move sets a critical precedent as the pharmaceutical industry approaches a "biosimilar cliff," with more low-cost alternatives entering the market.
隨着越來越多的低成本替代品進入市場，製藥行業接近 「生物仿製藥懸崖」，這一舉措開創了重要的先例。
Last month, UnitedHealth Group Inc. (NYSE:UNH) said it would remove Humira from some of its preferred reimbursement lists starting January 1, 2025. The company will recommend lower-cost biosimilar versions instead.
上個月，UnitedHealth Group Inc.（紐約證券交易所代碼：UNH）表示，將從2025年1月1日起將Humira從部分首選報銷清單中刪除。該公司將改爲推薦成本較低的生物仿製藥版本。
Price Action: ABBV stock is down 0.45% at $195.93 at the last check on Thursday.
價格走勢：在週四的最後一次支票中，ABBV股價下跌0.45％，至195.93美元。
- Amazon's Profitable Essential Merchandise, Efficiency Gains Set To Drive Growth: Analyst
- 分析師：亞馬遜利潤豐厚的必需商品，效率提高將推動增長
Photo via Wikimedia Commons
照片來自維基共享資源
